{"title":"The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease.","authors":"Ilkay S Idilman, Musturay Karcaaltincaba","doi":"10.14744/hf.2023.2023.0004","DOIUrl":null,"url":null,"abstract":"MRE can also be used in the follow-up of NAFLD patients nonin-vasively. A recent study showed a 15% increase in MRE-LSM is the strongest predictor of progression to advanced fibrosis in patients with NAFLD. [10] Tamaki et al. [7] also proposed that a combination of MRE with FIB-4 score (MEFIB index) can be used for detecting patients with NAFLD and significant fibrosis for enrollment in NASH clinical trials. Beyond that, MRE-LSM is shown to be a significant predictor of the development of cirrhosis as well as baseline LSM is predictive of the development of liver-related events such as decompensation or death. [11] A recent study that evaluated the MEFIB index showed excellent negative predictive value for hepatic decompensation in patients with NAFLD-related cirrhosis. In this study, the investigators also observed that MRE-LSM is associated with hepatic decompensation, hepatocel-lular carcinoma, and death in patients with NAFLD-related cirrhosis. [12] In conclusion, MRE-LSM is a useful tool for the detection and assessment of hepatic fibrosis in patients with NAFLD. MRE-LSM can also be used for the evaluation of disease progression as well as the predic-tion of disease courses in NAFLD patients.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/60/hf-4-001.PMC9951892.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2023.2023.0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
MRE can also be used in the follow-up of NAFLD patients nonin-vasively. A recent study showed a 15% increase in MRE-LSM is the strongest predictor of progression to advanced fibrosis in patients with NAFLD. [10] Tamaki et al. [7] also proposed that a combination of MRE with FIB-4 score (MEFIB index) can be used for detecting patients with NAFLD and significant fibrosis for enrollment in NASH clinical trials. Beyond that, MRE-LSM is shown to be a significant predictor of the development of cirrhosis as well as baseline LSM is predictive of the development of liver-related events such as decompensation or death. [11] A recent study that evaluated the MEFIB index showed excellent negative predictive value for hepatic decompensation in patients with NAFLD-related cirrhosis. In this study, the investigators also observed that MRE-LSM is associated with hepatic decompensation, hepatocel-lular carcinoma, and death in patients with NAFLD-related cirrhosis. [12] In conclusion, MRE-LSM is a useful tool for the detection and assessment of hepatic fibrosis in patients with NAFLD. MRE-LSM can also be used for the evaluation of disease progression as well as the predic-tion of disease courses in NAFLD patients.